The FDA approved a supplemental application for Enhertu (fam-trastuzumab deruxtecan-nxki) on December 15, 2025. This approval pertains to an efficacy supplement, indicating an expansion or modification of the drug's approved uses based on new data demonstrating its effectiveness.
Background
Enhertu (fam-trastuzumab deruxtecan-nxki) is a drug developed by DAIICHI SANKYO. The FDA's approval of a supplemental application for efficacy means that new clinical data has been submitted and reviewed, demonstrating the drug's effectiveness for an expanded or modified use. This could include a new indication, a different patient population, or an updated dosing regimen, all supported by clinical evidence of benefit.
What this means
This supplemental efficacy approval for Enhertu marks a significant development in its regulatory status. While specific details of the new indication or patient population are not provided in this summary, such approvals typically expand the therapeutic scope of a drug. For healthcare providers, this could translate into new treatment guidelines or expanded options for patients who may benefit from Enhertu. Researchers will find this update relevant for understanding the evolving landscape of approved therapies, and patient advocates can use this information to inform their communities about potential new treatment avenues. The FDA's decision is based on a thorough review of new clinical data, underscoring the drug's demonstrated efficacy in the context of the supplemental application.
Source
This information was sourced from the FDA's official database. The approval of supplemental application BLA 761139 S-38 for Enhertu (fam-trastuzumab deruxtecan-nxki) was recorded on December 15, 2025, and is publicly accessible on accessdata.fda.gov.